Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Payables (2016 - 2025)

vTv Therapeutics' Payables history spans 12 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Payables rose 30.44% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 30.44%, while the annual FY2025 figure was $6.6 million, 30.44% up from the prior year.
  • Payables for Q4 2025 was $6.6 million at vTv Therapeutics, down from $10.1 million in the prior quarter.
  • Across five years, Payables topped out at $12.5 million in Q1 2022 and bottomed at $4.2 million in Q1 2025.
  • The 5-year median for Payables is $7.4 million (2022), against an average of $7.6 million.
  • The largest YoY upside for Payables was 312.1% in 2021 against a maximum downside of 57.93% in 2021.
  • A 5-year view of Payables shows it stood at $8.3 million in 2021, then fell by 8.96% to $7.5 million in 2022, then surged by 38.42% to $10.4 million in 2023, then crashed by 51.82% to $5.0 million in 2024, then surged by 30.44% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Payables are $6.6 million (Q4 2025), $10.1 million (Q3 2025), and $5.2 million (Q2 2025).